CClinicalTrials.gg
CompletedNCT07192523Updated Jan 5, 2026

Effects of Different Fluid Transfusion Regimens On Glycocalyx In Patients Undergoing Thoracic Surgery.

An interventional study of Restrictive fluid therapy and Liberal fluid therapy in Hypervolemia and Hypovolemia, sponsored by Kocaeli Derince Education and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Kocaeli Derince Education and Research Hospital · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Introduction: Endothelial Glycocalyx (EG) composing of proteoglycans heparan sulfate (HS), syndecan, and plasma proteins forms a physiologically active surface layer on the vascular endothelium, regulates oncotic pressure. We aimed to compare the effects of two different fluid transfusion regimens on EG.

Materials and Methods: 41 patients with ASA I-III physical status were included in this prospective, randomized controlled study. We collected blood samples before anesthesia induction and after surgery to measure hemoglobin-hematocrit levels and biochemical parameters. Hemodynamic parameters were recorded every 15 minutes perioperatively. We divided the patients into two groups: Group R received 3 ml/kg/h, and Group L received 8 ml/kg/h of Ringer's lactate infusion. To assess endothelial damage, HS and syndecan levels, blood samples were taken after anesthesia induction(T1), after pneumonectomy or lobectomy(T2), and at the end of surgery(T3).

Read the detailed description

This prospective, randomized-controlled study was conducted between August 15, 2021, and December 15, 2021, at a University Hospital. Local ethics committee approval (protocol no: 2019/514/154/10) was obtained for the study. The study was conducted in accordance with the Declaration of Helsinki. Written and verbal consent was obtained from all patients included in the study.

Participants 41 patients who underwent elective thoracic surgery were included in the study. Inclusion criteria; being 18-65 years old and in the American Society of Anaesthesiologists (ASA) I-III risk group. Exclusion criteria from the study were determined as not accepting to participate in the study, having heart failure, having a previously known vascular disease, and having more than 500 ml of blood replacement during the perioperative period.

Anesthesia protocol Patients were restricted from consuming solid and semi-solid food 6 hours before the operation. Water consumption was allowed until 2 hours before the operation. After all patients were taken to the operation room, standard monitoring techniques including electrocardiogram (ECG), pulse oximetry (SpO2), end-tidal carbon dioxide pressure (ETCO2), non-invasive blood pressure and body temperature monitoring were applied, and a Foley urinary catheter was inserted. After a 25 G intravenous (iv) catheter was opened on the back of the hand, 1-1.5 mg/kg propofol, 1-2 mcg/kg fentanyl and 0.6 mg/kg rocuronium were administered for general anesthesia induction, and tracheal intubation was performed with a No. 7.5 double lumen tracheal tube. After intubation, fresh gas flow was adjusted to 2lt/min (50% oxygen and 50% air). For maintenance of anesthesia, sevoflurane was titrated at a concentration of 2-2.5% to maintain MAC 1 and BIS 40-60. In intraoperative fluid therapy, one group (Group Restrictive (Group R)) received 3ml/kg/hr, and the other group (Group Liberal (Group L)) received 8ml/kg/hr crystalloid (Ringer Lactate). Blood replacement was applied according to the hemodynamic data and bleeding amounts of the patients. Blood samples were taken from the patients for hemogram, BUN, and creatinine measurements before and after surgery. Twenty minutes before the end of the operation, all patients were administered tramadol 100 mg and paracetamol 1 gr intravenously for postoperative analgesia. After the end of the surgery, 0.015 mg/kg atropine and 0.04 mg/kg neostigmine were administered to the patients for decurarization. Following extubation with adequate muscle strength and spontaneous ventilation, the patients were taken to the postoperative care unit.

Collection of Blood Samples To evaluate endothelial damage, blood samples were taken from patients in both groups 3 times. The time of taking the samples was determined as; the blood sample taken after the placement of the IV cannula (T1), the blood sample taken after pneumonectomy or lobectomy (T2), and the blood sample taken after the patient was extubated following the end of surgery (T3). Venous blood samples were placed in a 5 ml vacuum tube with a serum separator. The samples were centrifuged at 1500 g for 10 minutes to separate the serum, and these samples were stored at -80 °C.

Biochemical analysis Studies for the analysis of heparan sulfate and syndecan phosphate parameters were carried out in the Medical Biochemistry Laboratory of our University Faculty of Medicine. The serum concentration of Syndecan-1 was determined using the enzyme-linked immunosorbent assay (ELISA) technique. Serum syndecan-1 levels were analyzed using an ELISA kit (catalog no. E3344Hu.), purchased from BT-laboratory. Ltd. (City, China) following the manufacturer's instructions, and the results are expressed in ng/ml. The intra-assay coefficient of variation (CV) of Syndecan-1 was \<8% and the inter-assay CV was \<10% for this parameter.

02

Conditions studied

  • Hypervolemia
  • Hypovolemia

Browse trials for

Keywords

  • Endothelial Dysfunction
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

. Being 18-65 years old and in the American Society of Anaesthesiologists (ASA) I-III risk group.

Exclusion criteria

Exclusion Criteria:

  • Having heart failure
  • Having a previously known vascular disease
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Other
    Effects of 3ml Fluid Transfusion Regimens On Glycocalyx

    In intraoperative fluid therapy, Group Restrictive received 3ml/kg/hr Ringer Lactate

    Other: Restrictive fluid therapy

  • Other
    Effects of 8 ml Fluid Transfusion Regimens On Glycocalyx

    In intraoperative fluid therapy, one group Group Liberal received 8ml/kg/hr crystalloid Ringer Lactate.

    Other: Liberal fluid therapy

Interventions

  • OtherRestrictive fluid therapy

    Group Restrictive (Group R) received 3ml/kg/hr, crystalloid (Ringer Lactate).

    Also known as: 3 ml

  • OtherLiberal fluid therapy

    Group Restrictive liberal received 8ml/kg/hr, crystalloid (Ringer Lactate).

    Also known as: 8 ml

05

What researchers measure

Primary outcomes

  1. Our primary aim in the study was to evaluate the changes in HS and syndecan 1 levels after 8 ml/kg/hr or 3 ml/kg/hr fluid transfusion in thoracic surgery.

    To evaluate endothelial damage, blood samples were taken from patients in both groups 3 times. The time of taking the samples was determined as; the blood sample taken after the placement of the IV cannula (T1), the blood sample taken after pneumonectomy or lobectomy (T2), and the blood sample taken after the patient was extubated following the end of surgery (T3). Venous blood samples were placed in a 5 ml vacuum tube with a serum separator. The samples were centrifuged at 1500 g for 10 minutes to separate the serum, and these samples were stored at -80 °C.

    Time frame: 6 month

06

Study locations

1 site
  • Kartal Dr Lutfi Kirdar City Hospital
    Istanbul, Kartal 34000, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07192523
Lead sponsor
Kocaeli Derince Education and Research Hospital
Responsible party
Tahsin Şimşek (ASSOCİATED PROFESSOR, Kocaeli Derince Education and Research Hospital) — Principal investigator
First posted
Sep 25, 2025
Start date
Aug 15, 2021
Primary completion
Dec 15, 2021
Completion
Aug 30, 2025
Last update
Jan 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion